Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
JAMA Oncology|July 17, 2015
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic LeukemiaKami J Maddocks, Amy S Ruppert, Gerard Lozanski, et al.Blood|January 14, 2014
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapyJennifer A Woyach, Kelly Smucker, Lisa L Smith, et al.Leukemia & Lymphoma|February 28, 2015
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997David M Lucas, Amy S Ruppert, Gerard Lozanski, et al.Leukemia|May 22, 2021
Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeqCaner Saygin, Eileen Hu, Pu Zhang, et al.Cancer Cell|May 26, 2012
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signalsRosa Lapalombella, Yuh-Ying Yeh, Liwen Wang, et al.The New England Journal of Medicine|May 30, 2014
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinibJennifer A Woyach, Richard R Furman, Ta-Ming Liu, et al.Haematologica|August 8, 2024
LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclaxresistant chronic lymphocytic leukemiaJanani Ravikrishnan, Daisy Y Diaz-Rohena, Elizabeth Muhowski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2017
BTK<sup>C481S</sup>-Mediated Resistance to Ibrutinib in Chronic Lymphocytic LeukemiaJennifer A Woyach, Amy S Ruppert, Daphne Guinn, et al.The Journal of Clinical Investigation|March 20, 2025
TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environmentPu Zhang, Ethan C Whipp, Sarah J Skuli, et al.Pageof 2